EBV+ PTLD IS AN UNPREDICTABLE THREAT FOR TRANSPLANT RECIPIENTS
Post-transplant lymphoproliferative disease (PTLD) is a lymphoid and/or plasmacytic proliferation that occurs as a result of immunosuppression in a setting of solid organ or allogeneic hematopoietic cell transplantation. PTLD can be Epstein-Barr virus (EBV) positive or EBV negative.1
Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) is a rare, acute, and potentially life-threatening lymphoma that presents challenges in the management of transplant patients.2 Staying connected to the latest scientific information, treatment guidelines, and useful resources about EBV+ PTLD can help you provide the best possible care for your patients.
Learn more about:
Post-transplant primary infection or viral reactivation
B cell
Epstein-Barr virus
Featured Resources
in HCT Patients
EBV+ PTLD Risk Factors
in HCT Patients
Dr Mohamad Mohty
Professor of Hematology, University Pierre & Marie Curie, Paris, France
One needs to be reminded that there are some specific risk factors that may aggravate or increase the incidence of viral reactivations like CMV or EBV or even the development of EBV PTLD. For example, a T-cell depletion whether in vitro or in vivo, the use of numerous immunosuppressive therapies, the use of high-dose steroids for a long-term period, the use of mismatched donors—all of these situations can lead to an increased risk of EBV reactivations and, at some point, development of EBV PTLD.
Post‐transplant Lymphoproliferative Disorders, Epstein‐Barr Virus Infection, and Disease in Solid Organ Transplantation
Clinical Transplantation
2019;33(9):e13652
References
1. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173-183. 2. Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Eng J Med. 2018;378(6):549-562.
